Drug Trial Radar · NCT06308198
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Mar 29, 2024
Primary completion
Feb 26, 2025
Study completion Feb 26, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to evaluate the safety and efficacy of AGN-151586 compared to placebo in adult participants. AGN-151586 is an investigational product being developed for the treatment of GL. In the first period, participants are randomly assigned to receive AGN-151586 or placebo. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. In the second period, all participants who meet retreatment criteria will receive open-label AGN-151586. Around 160 participants will be enrolled in the study at approximately 14 sites in China, Taiwan, and Japan. Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Eligible participants may then receive AGN-151586 injections on Day 43 and will be followed for up to 6 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care due to multiple study visits. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Glabellar Lines
Interventions
AGN-151586Drug
Intramuscular Injections
PlaceboDrug
Intramuscular Injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with a >= 2-Grade Improvement from Baseline on the Facial Wrinkle Scale with Asian (FWS-A) Guide According to Investigator Assessment of Glabellar Lines (GL) Severity at Maximum FrownTime frame: Day 7
- Percentage of Participants with a >= 2-Grade Improvement from Baseline on the FWS-A Guide According to Participant Assessment of GL Severity at Maximum FrownTime frame: Day 7
- Number of Participants with Adverse Events (AEs)Time frame: Up to approximately Day 84
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Beijing Hospital /ID# 256084
Beijing, Beijing Municipality, China
Dermatology Hospital of Southern Medical University /ID# 256172
Guangzhou, Guangdong, China
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 255871
Wuhan, Hubei, China
Nanjing Drum Tower Hospital /ID# 255936
Nanjing, Jiangsu, China
Zhongda Hospital Southeast University /ID# 255937
Nanjing, Jiangsu, China
Wuxi People's Hospital /ID# 256029
Wuxi, Jiangsu, China
Xianyang Hospital of Yan'an University /ID# 256774
Xianyang, Shaanxi, China
Huashan Hospital, Fudan University /ID# 255870
Shanghai, Shanghai Municipality, China
Zhejiang Provincial People's Hospital /ID# 256028
Hangzhou, Zhejiang, China
Tokyo Center Clinic /ID# 267380
Chuo-ku, Tokyo, Japan
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 260669
Kaohsiung City, Taiwan
Tri-Service General Hospital /ID# 260673
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.